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Abstract
Over 25% of the world's population are infected with helminth parasites, the majority of
which colonise the gastrointestinal tract. However, no vaccine is yet available for human
use, and mechanisms of protective immunity remain unclear. In the mouse model of Helig-
mosomoides polygyrus infection, vaccination with excretory-secretory (HES) antigens from
adult parasites elicits sterilising immunity. Notably, three purified HES antigens (VAL-1, -2
and -3) are sufficient for effective vaccination. Protection is fully dependent upon specific
IgG1 antibodies, but passive transfer confers only partial immunity to infection, indicating
that cellular components are also required. Moreover, immune mice show greater cellular
infiltration associated with trapping of larvae in the gut wall prior to their maturation. Intra-
vital imaging of infected intestinal tissue revealed a four-fold increase in extravasation by
LysM+GFP+ myeloid cells in vaccinated mice, and the massing of these cells around imma-
ture larvae. Mice deficient in FcRγ chain or C3 complement component remain fully im-
mune, suggesting that in the presence of antibodies that directly neutralise parasite
molecules, the myeloid compartment may attack larvae more quickly and effectively. Immu-
nity to challenge infection was compromised in IL-4Rα- and IL-25-deficient mice, despite
levels of specific antibody comparable to immune wild-type controls, while deficiencies in
basophils, eosinophils or mast cells or CCR2-dependent inflammatory monocytes did not
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diminish immunity. Finally, we identify a suite of previously uncharacterised heat-labile vac-
cine antigens with homologs in human and veterinary parasites that together promote full
immunity. Taken together, these data indicate that vaccine-induced immunity to intestinal
helminths involves IgG1 antibodies directed against secreted proteins acting in concert with
IL-25-dependent Type 2 myeloid effector populations.
Author Summary
Despite the high prevalence of gastrointestinal helminth parasites in human and animal
populations throughout the world, no vaccines are yet available and we lack understanding
of how anti-parasite protective immunity may operate effectively. We have used a model
system with a natural mouse nematode parasite,Heligmosomoides polygyrus, which estab-
lishes long-term chronic infection in laboratory mice through the secretion of immuno-
suppressive molecules. Immunization of mice with as few as 3 secreted proteins, collected
from parasites in vitro, confers complete immunity to challenge infection. We show here
that immunity requires specific IgG1 antibodies directed to the secreted products, acting
together with innate myeloid cells that require activation through the canonical Type 2 cy-
tokine receptor, IL-4Rα, as well as through a pathway not previously known to be involved
in effector mechanisms, IL-25. These myeloid cells act to trap and envelop helminth larvae
while in the submucosal tissues of the small intestine, massing in large numbers and pre-
venting their maturation and exit into the gut lumen. Thus the combined effects of specific
antibodies from the adaptive immune system, and Type 2 cytokine activation of the innate
immune system, co-operate to ensure elimination of the helminth parasite.
Introduction
The immune system has evolved suites of defense mechanisms to protect against infectious
pathogens of all types ranging from viral and bacterial micro-organisms to more complex eu-
karyotic fungi, protozoa and helminths. In contrast to our detailed knowledge of anti-microbial
immune mechanisms, however, we have yet to develop a clear picture of how immunity acts to
eliminate parasites such as gastrointestinal helminths which even today infect over 1 billion
people across the world [1].
The need to understand how the immune system can successfully eliminate helminth para-
sites is accentuated by the lack of appropriate new tools for control and eradication of these or-
ganisms. Although experimental models of protection show immunity to secondary challenge
following drug-abbreviated primary infection, drug-induced clearance of helminths does not
prevent rapid re-infection in human populations, and resistance to anthelmintic drugs has al-
ready emerged in veterinary use [2]. While vaccination would offer longer-term protection
from infection, there are no currently available human anthelminthic vaccines, and the mecha-
nisms of protective immunity on which new vaccines would depend have not been defined
[3,4].
Helminth infection is, under natural conditions, near-ubiquitous and the mammalian im-
mune system will have evolved specific mechanisms of activation and regulation to optimally
respond to their challenge. Hence it is also likely that studying pathways of immunity to hel-
minths will uncover new facets and properties of the immune system not apparent under
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conditions of infection with micro-organisms, and not necessarily predictable from our current
knowledge of Type 2 activation in anti-helminth immunity [5,6].
The quest for anti-helminth vaccines began with live, radiation-attenuated organisms,
which were effective in veterinary settings but unsuitable for human use [7]. Despite the suc-
cessful translation of one veterinary vaccine to a molecular subunit formulation [8], in all other
cases individual purified protein and recombinant vaccines have had modest effects, reducing
worm loads without inducing full sterilising immunity in vaccinated recipients. While human
trials have been initiated with partially-protective anti-hookworm and schistosome vaccines
[9], it would appear that greater insight into the cellular and mechanistic basis of anti-helminth
immunity, alongside the identification of protective antigens, will be essential if we are to en-
hance the choice and efficacy of future vaccines for human use.
Many helminths, of both humans and animals, are known to be highly immunomodulatory,
mediating their effects at least in part through their repertoire of soluble secreted proteins
which target the host immune system [10]. This has been particularly well-demonstrated in the
natural mouse helminth parasite,Heligmosomoides polygyrus, which successfully establishes
long-term infections in many strains of laboratory mice [11,12]. Immunomodulatory proper-
ties characterized in the H. polygyrus Excretory/Secretory (HES) products mediate a series of
immunosuppressive effects on dendritic cells [13], airway epithelial cells [14] and T cells
[15,16], prolonging parasite survival in an immunologically hostile environment.
In this study, we reasoned that if parasite secretions were promoting infection, that their
blockade should generate protective immunity in this model system. As we demonstrate below,
by immunizing mice with secreted products in an immunogenic fashion, we were able to gen-
erate complete protection against challenge infection. Protective immunization elicited IgG1
antibodies reacting against homologues of human vaccine candidates, as well as to several new
targets conserved in parasites of human and veterinary importance. However, whilst a strong
antibody response was a prerequisite for protection it alone was insufficient, and IL-25 signal-
ling was also required for the expulsion of adult worms. Using intra-vital imaging of the intesti-
nal mucosa, we show that protection is associated with enhanced recruitment and
extravasation of LysM+ myeloid cells. Thus we show below that the antigen-specific adaptive
response drives and unleashes a cytokine-dependent innate effector response for
parasite elimination.
Results
HES immunization generates early immunity against larval parasite
challenge
We have previously reported that immunization with the secreted products of adultH. poly-
gyrus (HES) confers potent immunity against challenge infection [17,18]. Using a standard
alum adjuvant regimen (Fig. 1A), we first showed that while HES vaccination generates sterile
immunity, as reflected by the complete absence of adult parasites at day 28 post-challenge, im-
munization withH. polygyrus somatic extract does not significantly reduce parasite numbers
(Fig. 1B). Adult worm fecundity, as measured by fecal egg counts, is an earlier and more sensi-
tive measure of immune attrition, by which HES vaccination is seen to elicit almost complete
immunity by day 14, while the effects of somatic extract immunisation are considerably more
modest (Fig. 1C).
The low level of eggs present in the feces of vaccinated mice at day 14 post-challenge
(Fig. 1C) indicated that immunity was acting early in infection. To confirm this we established
that at day 7 post-challenge, similar numbers of fourth-stage (L4) larvae are found in the intes-
tinal wall of vaccinated and control mice, but by day 14 the immune animals had eliminated
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Fig 1. HES vaccination elicits sterile immunity to challenge and blocks parasite maturation. A. Schematic protocol for immunization.B. Parasite
recoveries d 28 post-challenge following vaccination of C57BL/6 females with HES or somatic extract (HEx). Data shown are combined from two
experiments each of 4–5 mice per group. Significance determined by ANOVA.C. Faecal egg counts (d 14, 21, 28 post-challenge) from (B). Significance
determined by ANOVA.D. Parasite recoveries at d 7 (small intestinal wall) and 14 post-challenge (gut lumen). Representative of two independent
experiments. Significance determined by t-test. E. H&E sections of duodenum in control and vaccinated animals at d9 post challenge; parasites in control
animals are observed in gut lumen, but remain trapped in submucosa of vaccinated mice. Black circles indicate positions of parasite. Scale bar represents
100 μm.
doi:10.1371/journal.ppat.1004676.g001
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almost every helminth from the lumen (Fig. 1D). Notably, while worms in control mice had
migrated to the gut lumen by day 9, many of those in vaccinated mice remained trapped in the
gut wall (Fig. 1E). Thus immunity induced by HES vaccination is directed against the imma-
ture parasite, with worm immobilisation and expulsion taking place between the first and sec-
ond weeks of infection. In this respect, the molecular vaccine reproduces previous observations
of immunity against immature stages in mice rendered immune by prior infection and drug-
induced clearance of parasites [19,20].
The early host response was further characterized immunohistologically at the inflammato-
ry foci surrounding larvae in the intestinal sub-mucosa (Fig. 2A). By day 7, these inflammatory
foci have attracted large numbers of CD11b+ and Gr1+ myeloid cells, which localise more in-
tensely around the parasite in vaccinated mice (Fig. 2B). To gain a greater understanding of the
dynamic events that occur in vivo following parasite challenge, we used intra-vital two-photon
microscopy to image cells and larval parasites from the serosal side of the intact intestine in live
LysM-GFP mice, which have labeled neutrophils, monocytes and macrophages [21,22]. Early
in infection, at day 3 post-challenge, GFP+ leukocytes showed decreased rolling velocity, and
increased arrest and extravasation in non-vaccinated mice compared to naive controls; howev-
er, GFP+ cell arrest (Fig. 2C) and tissue infiltration was greatly enhanced in vaccinated recipi-
ents, with a>4-fold increase in tissue infiltrating cell numbers (Fig. 2D-F and S1 Movie A-C).
GFP+ infiltrating cells accumulated around parasite larvae which are still viable at day 5, but
particularly in the immune mice are constrained and partly immobilised by the cellular infil-
trate (S1D and E Movie).
Contrary to expectation, analysis of cell phenotypes in the intestinal tissue and draining
mesenteric lymph nodes showed little difference between control and vaccinated animals, with
similar levels of Th2 and Treg populations, although vaccinated mice have suppressed IFN-γ
expression in the MLN (S1A-D Fig). In the lamina propria of infected mice, CD11b+Ly6G+
granulocytes, and both Ly6C+ and Ly6C– CD11b+F4/80int macrophages, showed expansion in
all infected mice (S1E Fig), with a proportion of macrophages adopting an alternatively activat-
ed phenotype, characterised by expression of Ym1 and RELMα (S1F Fig). Notably, we observed
higher levels of Ym1 transcript in total gut tissue from vaccinated mice by qPCR (S1F Fig).
Immunity requires IgG antibodies but not activating FcR or complement
Immunity to H. polygyrus generated by prior infection is known to be dependent on B cells, ei-
ther or both through antibody and pro-Th2 cytokine production [19,23,24]. Vaccination in-
duced marked phenotypic changes in MLN B cells with IgG1 class-switched CD19+ cells
evident by day 7 post-challenge (Fig. 3A), alongside up-regulation of activation-associated
CD23 (FcεRII), and reduced CD21/CD35 expression (Fig. 3B). Immunisation also evoked high
titers of HES-specific IgG1 prior to challenge, as well as anti-HES IgA and E to a lesser degree
(Fig. 3C). To assess whether B cells were required for immunity, we vaccinated wild-type
C57BL/6 and congenic B cell-deficient μMTmice and found complete absence of immunity in
the latter, as reflected in their higher worm and egg burdens (Fig. 3D, S2A Fig). To distinguish
between humoral antibodies, and B cell-derived cytokines or signals, we also vaccinated MD4
mice with a fixed transgenic BCR for an unrelated protein, hen egg lysozyme (HEL). The in-
ability of MD4 mice to develop protective immunity (S2B, C Fig) indicated that production of
specific antibodies is critical for effective vaccination. Similar results were observed in CD40–/–
animals which were unable to class switch to parasite-specific IgG1 (S2D, E Fig), and which
(as μMTmice; Fig. 3D) showed significantly elevated parasite numbers in response to primary
infection (PBS control groups).
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Fig 2. HES vaccination promotes extensivemyeloid cell extravasation and accumulation around site of larval invasion. A. H&E staining of duodenal
sections from naïve and d 7 post-challenge PBS control or HES-immunized C57BL/6 mice. Arrows indicate position of parasites.B. Immunohistology
showing recruitment of CD11b+ (green) and Gr1+ (red) myeloid cells. Representative of 3–4 mice per group. Scale bar in A-B represents 100 μm. C. Rolling
velocities of LysM-GFP+ cells along vessels imaged by two-photon microscopy of duodenum from the serosal aspect. Data accumulated from two mice per
group, 3–7 vessels per mouse. Vessels were selected on basis of showing rolling behaviour. Significance determined by Kruskal-Wallis test.D. Tissue
infiltration of LysM-GFP+ cells surrounding vessels in (C). Significance determined by t-test. E, F. Examples of two-photon microscopy from (D) showing
tissue-infiltrating LysM-GFP+ cells in PBS- and HES-vaccinated mice. Scale bar represents 50μm. See also Supplemental Movie S1.
doi:10.1371/journal.ppat.1004676.g002
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Fig 3. Immunity is dependent on cognate B cells and partially transferrable by antibody. A. Gated CD19+ MLN cell expression of cell surface IgM and
IgG1 in naïve and d 7 and d 14 post-challenge PBS and HES B6 mice. B. Gated CD19+ MLN cell expression of cell surface CD21/CD35 (CR2/CR1) and
CD23 (FcεRII) in naïve and d 7 post-challenge PBS and HES B6 mice. Numbers represent geoMFI of CD23 (blue) and CD21/CD35 (red) expression. A-B
representative of two independent experiments with 3–5 mice per group.C. Pre-challenge anti-HES IgM, IgG1, IgG2c, IgA and IgE titers in PBS and HES
vaccinated B6 mice with 5 mice per group.D. Day 28 post-challenge worm burdens from C57BL/6 and μMTmice following HES immunization or PBS
control. Data pooled from two experiments. Significance determined by ANOVA as indicated. E, F. Day 28 post-challenge worm and fecal egg burdens (d 14,
21, 28) in naïve C57BL/6 mice receiving IgG from vaccinated or primary infected mice, or PBS, as detailed in materials and methods. Data are pooled from
two experiments, with significance determined by ANOVA Vs C57BL/6 PBS.G. Day 21 post-challenge adult worm burdens in C57BL/6 and FcRγ–/–x C3–/–
mice following HES immunization or PBS control. Significance determined by t-test as indicated. See also S2 Fig.
doi:10.1371/journal.ppat.1004676.g003
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We next directly tested the protective potential of antibodies by passive transfer of purified
IgG (predominantly IgG1, Fig. 3C) from the serum of HES-vaccinated animals into naïve re-
cipients. Transfer resulted in significant reductions in adult worm (Fig. 3E), and egg (Fig. 3F)
numbers, but not to the same extent as HES immunization. However, it was also noted that
IgG transfer did not raise circulating anti-HES IgG1 titers in recipients to the same level as
HES immunization (S2F Fig), and hence sterile immunity may require either extremely high
antibody titers, or the activation of additional protective effector cell populations.
We next wished to see whether the protective antibody response was dependent on either
activating FcR signalling and / or complement fixation. Vaccination of FcRγ–/–x C3–/– double
transgenic mice resulted in undiminished immunity (Fig. 3G) showing that neither FcR signal-
ling nor complement activation is required for protection. This suggests that HES immunisa-
tion generates protective IgG1 antibodies that function by binding to, and directly neutralising
the function of, essential parasite excretory / secretory (ES) molecules.
Immunity requires IL-4 signaling, but is independent of eosinophils, mast
cells, basophils and CCR2+ inflammatory monocytes
To investigate cellular effector components that may be required to complement the protective
effects of IgG1 antibodies, we first confirmed that immunity is fully dependent upon IL-4R sig-
nalling. Thus, vaccinated IL-4Rα-/- mice fail to expel worms and actually incurred higher egg
burdens than wild-type controls (Fig. 4A, S3A Fig), despite generating HES-specific IgG1 re-
sponses similar in titre to those seen in B6 primary infection (S3B Fig), and equivalent in speci-
ficity to immunised wild-type mice (S3C Fig).
We then investigated type 2 effector populations using gene-targeting or antibody-depletion
approaches as appropriate. Because of the marked expansion in eosinophil numbers in MLNs
of vaccinated mice (S3D Fig), we assessed immunity in two models of eosinophil deficiency,
C57BL/6 IL-5–/– mice and BALB/c Δdbl-GATA-1 mice (S3E-F Fig). Both eosinophil-deficient
genotypes were fully protected from infection by HES vaccination (Fig. 4B and S3G Fig) and in
both models anti-HES IgG1 titers were indistinguishable from wild-type mice (S3H, I Fig). Eo-
sinophils have a role in killing parasites that are trapped in the intestinal wall of vaccinated
mice, as a small but significant number of live worms (<40) were recovered from this site at
day 21 post-challenge in vaccinated Δdbl-GATA-1 mice, but not BALB/c controls (Fig. 4C).
Furthermore, PBS treated control Δdbl-GATA-1 mice had higher parasite burdens than their
WT BALB/c counterparts, suggesting eosinophils have a role in the control of primary infec-
tion in this more resistant genotype (Fig. 4B).
Two other cells types thought to be important in Th2 mucosal immunity are mast cells and
basophils. Mast cells gradually accumulate in the intestine of both control and vaccinated mice
following challenge (S3J Fig). To focus on their potential role as effectors, rather than inducers,
of type-2 immunity [25], we used the depleting anti-c-kit mAb (ACK-2) at the time of chal-
lenge. ACK treatment effectively depleted splenic mast cells, blocked serum mast cell protease
mMCP-1 elevation and reduced intestinal levels (S3K-M Fig). Despite this, vaccine-induced
immunity remained intact (Fig. 4D). The role of basophils was then assessed by immunization
of basophil-deficient Mcpt8-Cre mice [26]. Again, HES vaccination rendered the mice fully re-
sistant (Fig. 4E), indicating that immunity is intact in the absence of basophils as well as eosin-
ophils and mast cells.
Similar genetic tools to selectively deplete other myeloid populations are less straightfor-
ward, and hence we employed clodronate depletion of phagocytes as previously described to
impair immunity to secondary infection with H. polygyrus [27]. We found this treatment re-
sults in high haemorrhage-associated mortality (60–70%) in vaccinated andH. polygyrus-
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challenged mice, although the surviving mice remained immune. Because of the clear recruit-
ment of Ly6C+ monocytes to the intestine following challenge (S1E Fig), and the requirement
for IL-4R-dependent alternatively activated macrophages (AAMs) in resistance to secondary
infection with H. polygyrus [27], we vaccinated and challenged CCR2-/- mice. Despite the se-
vere reduction of circulating monocytes in these mice [28], they showed full immunity
(Fig. 4F). As such, whilst Ly6C+ monocyte influx may represent part of the normal intestinal
response to a variety of inflammatory insults [29–31] it is not required for successful anti-
helminth immunity. Instead, we observed significant mortality in infected control (but not vac-
cinated) CCR2–/– mice, similar to that following clodronate treatment, revealing a key role for
monocyte recruitment in either repairing parasite-induced damage as it migrates across the in-
testine, preventing bacterial translocation, or regulating the potentially pathogenic inflamma-
tory response [31,32].
Protection requires IL-25 signaling, independent of antibodies
Recent studies have shown a key role for IL-25 (IL-17E) in the induction of protective anti-
helminth immunity [33], and for IL-17A in promoting helminth-induced inflammation [34].
Fig 4. Vaccine-induced immunity requires IL-4R-mediated signaling but not eosinophils, mast cells, basophils or CCR2+ monocytes. A-F. Day 21–
28 worm counts in control and vaccinated (A) C57BL/6 and IL-4Rα–/–mice, (B-C) BALB/c and GATA-1 Δdbl mice, (D) ACK-2-treated and control C57BL/6
mice, (E) C57BL/6 4get/Mcpt8 cre and 4get controls and (F) CCR2–/– and C57BL/6 controls. n.b. PBS/alum immunized CCR2–/–mice died or were culled
between 7–9 days post-challenge, with significant intestinal bleeding observed. Luminal worms in (A, B, D, E, and F), whereas counts in (C) represent live
worms recovered from the intestinal wall at day 21 (i.e. presumed non-migratory parasites). Data in (A, B, C, E and F) pooled from 2 independent
experiments. Significance in (A), (C) and (D) determined by ANOVA, in (B) by Kruskal-Wallis test, and (E-F) by unpaired t-test. See also S3 Fig.
doi:10.1371/journal.ppat.1004676.g004
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To test if either IL-25 or IL-17A was important for vaccine-induced immunity, we first immu-
nised mice deficient in IL-17RA (the shared receptor subunit for both IL-17 and IL-25), and
found identical anti-HES IgG1 titers compared to WT animals (Fig. 5A), indicating neither IL-
17 nor IL-25 signalling is required for alum adjuvant-induced antibody production. Surprising-
ly, HES immunisation failed in these mice (Fig. 5B), with all mice containing worms at day 28
Fig 5. Vaccine-induced immunity requires IL-25. A. Anti-HES pre-challenge IgG1 titres in control and vaccinated C57BL/6 and IL-17RA-deficient mice. B,
C. Day 28 worm counts and fecal egg burdens (d 14, 21 and 28) in control and vaccinated C57BL/6 and IL-17RA-deficient mice.D. Intracellular IL-4
production by naïve and d 7 post-challenge CD45+CD4+ lamina propria cells from C57BL/6 and IL-17RA–/–mice. Pooled from two experiments. E. Proportion
of lamina propria CD45+CD11b+Ly6G+ in naïve, d 3 and d 7 challenged C57BL/6 and IL-17RA–/–mice. F. Adult worm burdens (d 16) in control and
vaccinated C57BL/6 mice treated with anti-Ly6G (clone 1A8; left) or anti-Gr-1 (clone RB6-3C5; right) as detailed in materials and methods.G. Adult worm
burdens (d 28) in primary infected BALB/c mice treated with anti-Ly6G, anti-Gr-1, or rat IgG control, as in (F). H. Day 28 worm counts in control and
vaccinated C57BL/6 and IL-25-deficient mice. Significance in (A-E, G-H) determined by unpaired t-test or Mann-Whitney test, significance in (F) determined
by ANOVA Vs PBS control. Data from A-G pooled from 2 independent experiments. See also S4 Fig.
doi:10.1371/journal.ppat.1004676.g005
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(range 1–214), many having worm burdens similar to non-vaccinated controls. Vaccination
did impair egg production, indicating that a qualitatively lower level of functional immunity
was induced in the absence of IL-17/25 signalling (Fig. 5C).
IL-25 expands lineage-negative innate lymphoid ILC2s that promote Th2 differentiation
[33], but intestinal ILC IL-5 production was unimpaired in IL-17RA–/– mice (S4A Fig) and
only a minor decrease in Th2 response was seen following challenge (Fig. 5D). It is important
to note that in contrast to studies with the intestinal nematode Nippostrongylus brasiliensis
[33,35,36] ILC2 expansion following H. polygyrus infection or challenge is relatively limited in
susceptible wild-type C57BL/6 mice [12]. The muted induction of ILC2s byH. polygyrus im-
plies that the parasite may have evolved effective means to suppress innate immune reactivity,
such as that reported recently in the blockage of IL-33 release by its secreted products [14]. In-
stead, the major defect in IL-17RA-/- mice was impaired early recruitment of CD11b+Ly6G+
cells to the intestine (Fig. 5E). Cell sorting revealed these cells to have an irregular ring nucleus
(S4B Fig), as observed in “type 2” neutrophils elicited by N. brasiliensis infection [37]. Because
IL-17 family cytokines (including both IL-17 and IL-25) stimulate neutrophilia, we determined
whether neutrophil depletion would abolish vaccine-induced immunity toH. polygyrus. Using
antibodies that deplete either Ly6G+ cells (with 1A8 antibody) or all Gr-1+ cells (with RB6-8C5
antibody to both Ly6C and Ly6G), we established that immunity following vaccination was un-
affected by the loss of neutrophils (Fig. 5F). However, as reported previously [38], resistance to
primary infection (assayed in the more resistant BALB/c strain) is reduced by neutrophil deple-
tion, showing that these cells can contribute to protection in the setting of partial immunity
(Fig. 5G).
Because the IL-17RA–/– genotype does not distinguish between IL-17A and IL-25 signalling,
we next immunised IL-25–/– mice and found them to have a similar deficiency in vaccine-
induced protection, indicating that IL-25 is an important factor in expressing protective immu-
nity in this model, independent of parasite-specific antibodies, (Fig. 5H), and that ablated IL-
25 signalling can account for the phenotype of the IL-17RA–/– mouse, consistent with other
data from our laboratory showing that antibody neutralisation of IL-17 does not influence sus-
ceptibility toH. polygyrus infection [39].
HES contains multiple protective components
To identify individual protective antigens within HES, we first established that immunity is
elicited by heat-labile targets, rather than the abundant heat-stable glycans we recently identi-
fied [17]. Despite inducing similar titers of anti-HES IgG1 to native HES (S5A Fig), heat-
denaturation markedly impaired the protective capacity of HES with all heat-treated HES
immunised animals harboring between 1–90 adult parasites at day 28 (Fig. 6A). Nevertheless,
heat-treated HES immunisation was still able to promote reductions in egg burdens (Fig. 6B).
We then identified the dominant antigenic targets recognised by antibodies from vaccinated
mice, using immunoprecipitation of native biotin-labeled HES, because key heat-sensitive epi-
topes are not detected byWestern blot [17]. This analysis identified a restricted number of anti-
gens, including known venom allergen-like (VAL) proteins, VAL-1, 2 and 3, and to a lesser
extent VAL-4, as well as several additional spots (Fig. 6C).
Next, we purified native VAL-1, 2 and 3 with specific monoclonal antibodies [17], providing
also a fraction of HES devoid of these three dominant antigens (S5B-F Fig). Mice immunised
with HES or with a cocktail of VAL-1, 2 and 3 generated IgG1 antibodies against these pro-
teins, whereas mice given VAL-depleted HES failed to do so, while generating antibodies to
other specificities (S5G-J Fig). Immunisation with the three major VAL immunogens induced
a high, if not quite complete, level of protection against challenge (Fig. 6D, S5K Fig). Although
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5/10 mice harbored up to 4 adult parasites, with eggs detected in 7/10 mice at day 28, this rep-
resented a highly significant reduction compared to levels in control animals. In contrast, HES
depleted of the three major VAL proteins induced robust sterile immunity to challenge infec-
tion (Fig. 6D), with no eggs detected from day 21 (S5K Fig). The antibody targets in VAL-1/2/3
depleted HES (Fig. 6E, F) were then identified by mass spectrometry of antigens immunopre-
cipitated by the appropriate vaccinated mouse sera as four additional members of the VAL
Fig 6. Identification of protective antigens following HES immunization. A-B. Day 28 post-challenge worm and fecal egg burdens (d 14, 21, 28) in
C57BL/6 mice immunized with native or heat-treated HES. Data pooled from two experiments. Significance determined by ANOVA as indicated. C.
Protective antibody targets revealed by immunoprecipitation of biotin-labeled HES by serum antibodies from immunized mice. Immunoprecipitated proteins
were separated by pI (range 3–10) and molecular weights (indicated in kDa) and visualized with streptavidin HRP. Blue, red, green and brown circles
represent VAL-1, 2, 3 and 4, respectively. Unknown antigens circled black. Sera pooled from 5 HES-vaccinated C57BL/6 mice pre-challenge and
representative of two independent experiments. D. Day 28 post-challenge worm burdens from C57BL/6 mice immunized with a combination of VAL-1,-2 and
-3, or with HES depleted of these 3 antigens. Data pooled from two experiments. Significance determined by ANOVA Vs PBS/alum. E-F.
Immunoprecipitation of biotin-labeled HES antigens with vaccination sera as (C) frommice immunized with VAL-1/2/3 (E), or VAL-1/2/3 depleted HES (F).G.
LC-MS/MS identification of antibody targets in mice immunized with VAL-1/2/3-depleted HES, performed on samples of unlabeled HES immunoprecipitated
with serum antibodies from these mice. Proteins ranked according to spectral count (“count”). “Unique” represents number of unique peptide sequences in
identification, “score” is Mascot score, and emPAI estimated abundance also shown. Highest scoring BLAST homolog with expect values indicated. H. Day
28 post-challenge worm burdens from C57BL/6 mice immunized with HES or HES depleted of VAL-1, -2, -3 and -4. See also S5 Fig.
doi:10.1371/journal.ppat.1004676.g006
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superfamily (particularly VAL-4) as well as a lysozyme, two novel proteins and several others
with homologs in other parasitic and non-parasitic nematodes (Fig. 6G). We then further de-
pleted HES of VAL-4 (S5L, M Fig), in addition to VAL-1, 2, and 3, and found it to again fully
protect against challenge (Fig. 6H). These results show that the protective components in HES
include VAL proteins, as well as additional non-VAL proteins, which are likely to be protective
in combination.
Discussion
Together these studies show that immunization with secreted products from a gastrointesti-
nal helminth induces long-lived sterile immunity against challenge infection through IgG1
antibodies acting in parallel with IL-4Rα- and IL-25-dependent effector cells. The ability of
adult HES to drive immunity to immature stages is consistent with proteomic data
demonstrating extensive antigen sharing between adult and larval secretomes, and the effica-
cy of ES from day 5 larvae in inducing full immunity [18]. Protective antibodies target both
proteins of the VAL/ASP family that are known vaccine candidates [40], one of which in-
duces natural IgE in exposed human populations [41], as well as non-VAL proteins with ho-
mologs in medically and veterinary important parasites. As antibodies induce protection in
the absence of Fc receptor signalling, we suggest that they directly neutralise the function of
parasite secretions.
Whilst antibodies reduce parasite fitness as reflected by egg production, they cannot alone
lead to complete clearance of intestinal worms, which requires additional cytokine (IL-4Rα/IL-
25)-stimulated cell population(s). We therefore hypothesise that protective antibodies neutral-
ise parasite products that, in unvaccinated mice, are able to block the function of protective
host innate cells. Such a model is consistent with greater myeloid cell recruitment to the intes-
tine in vaccinated mice. Importantly, this suggests that successful vaccination against a mucosal
pathogen may simply require the induction of sufficiently high titers of neutralising antibody
to liberate host innate cells from parasite immunomodulation, allowing them to effect larval
damage and killing.
While the ability of most HES-immunized mice to mount effective anti-larval immunity is
striking, it is also notable that a small number of viable adult parasites survive to briefly pro-
duce eggs before they are also expelled. Two scenarios could explain this finding. First, para-
sites may be sufficiently damaged and stunted by immune attack in the tissues that their tenure
in the luminal environment is short-lived. Secondly, there may be a distinct mechanism for ex-
pulsion of luminal parasites such as occurs to remove N. brasiliensis, whose tissue phase is
within the lung. However, both tissue and luminal immunity appear to fully require activation
through type 2 cytokines, and share many molecular and cellular pathways.
The dependence of helminth immunity on IL-4Rα signalling is a central paradigm estab-
lished across many different systems [5,42] and suggests that indeed multiple Type 2 effector
mechanisms are involved in elimination ofH. polygyrus. However, we found that immunity in
vaccinated mice was intact in the absence of various innate cell types reported to perform es-
sential type-2 functions in other settings. For example, basophil-deficient Mcpt8Cre mice are
more susceptible to primary infection with a related nematode, Nippostrongylus brasiliensis
[26] and display impaired secondary immunity toH. polygyrus infection [43], yet are fully pro-
tected by HES vaccination. Likewise, mast cell-deficient Wsh mice are unable to clear primary
H. polygyrus infection [25], but vaccine immunity is intact animals depleted of mast cells with
ACK-2 antibody.
Eosinophils play intriguing roles in nematode infections, eliminating tissue-migrating larvae
of some species [44–46], while in fact enhancing the survival of others [47]. In our system, the
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absence of eosinophils did incur higher primary levels of infection, but no deficit in immunity
to challenge was observed other than greater viability of trapped larvae. Similarly, antibody de-
pletion of neutrophils compromises resistance to primary infection but not vaccine-induced
immunity to this parasite. So, whilst neutrophils may have some role in priming lung macro-
phages that promote early expulsion of N. brasiliensis following secondary challenge [37], they
are not required for worm expulsion in the more chronic H. polygyrusmodel. An interesting
observation is the expansion of CD11b+GR1+ subsets in the lamina propria, with phenotypes
similar to myeloid-derived suppressor cells. However, they are unlikely to block immunity to
the parasite as anti-Gr1 antibody compromises resistance to primary infection, and in the case
of N. brasiliensis are able to promote expulsion of the luminal parasites [48,49].
Our finding that IL-25 is essential for vaccine-driven effector responses is somewhat sur-
prising because it has been largely considered to be (alongside IL-33 and TSLP) a key inducer
cytokine, acting at an early stage to drive ILC2s, mastocytosis and, in turn, Th2 immunity
[50–55]. Whilst immunity toH. polygyrus is independent of TSLP [56] and IL-33 [57], IL-25
has a role in the partially protective response to primary infection [57]. Our data show that,
whilst IL-25 is essential for the effector response that dislodges parasites from the intestine, it
has little or no role in Th2 induction or the production of parasite-specific antibodies. This is
most consistent with recent findings showing IL-25-deficiency does not to compromise the ini-
tiation of type 2 responsiveness following N. brasiliensis infection, but rather acts at a later
stage to reduce immunity in both primary and challenge settings [58].
Interestingly, IL-25 is a key component in airway hypersensitivity, and antibody blockade of
IL-25 in airway allergy was found to be most complete during the effector, rather than sensiti-
zation, phase [59]. Moreover, an IL-25-responsive myeloid cell was found to mediate allergic
pathology in the lungs [60]. Although innate lymphoid cells, multipotent progenitor (mpp2)
cells [61,62] and iNKT cells [63–65] are also responsive to IL-25, there are no data implicating
any of these populations in the effector phase of anti-helminth immunity. Nevertheless, future
studies will require lineage-specific deletions of the IL-25-specific receptor subunit (IL-17BR)
to determine which populations are required to respond to this cytokine in the protective re-
sponse to infection.
Resistance to secondary infection withH. polygyrus, following drug-induced clearance of
primary parasites, is blocked by clodronate-loaded liposome depletion of phagocytes or phar-
macological inhibition of Arginase-1, a key product of alternatively activated macrophages
[27], while immunity to primary infection in genetically resistant mice is likewise compromised
by clodronate administration [12]. In primary H. polygyrus infection, alternatively-activated
macrophages adhere and immobilise tissue larvae [20], while transfer of macrophages (activat-
ed through IL-33) stimulates worm expulsion from chronically infected mice [66].
As has been noted elsewhere [67], the origin of intestinal macrophages during helminth-
induced inflammation remains uncertain, and hence it is significant that immunity remains
intact in CCR2-deficient mice. Monocyte egress from the bone marrow is impaired in these
mice [28], and CCR2 ligation is also required for tissue entry, at least in Type 1 inflammatory
settings [29]. Hence, immunity to H. polygyrusmay be mediated by the coordinated
recruitment of multiple (macrophage and non-macrophage) myeloid cell types utilising alter-
native receptors, but similarly driven through IL-4Rα and IL-25 to engage a similar effector
gene program (including, for example, Arginase-1) to maximise immunity to the near-
ubiquitous threat of gastrointestinal helminth parasites. Future work will be directed towards
establishing if a suite of protective genes acting against helminth infection can be so defined,
and if so the nature of their gene products and the range of cell phenotypes responsible for
their production.
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Materials and Methods
Mice, parasites, ES and extract preparation, immunization and antibody
treatment
Mice were bred in house and kept in individually ventilated cages according to national guide-
lines. Transgenic strains were kindly provided as follows; C57BL/6 IL-17RA–/– mice [68] by
Prof B. Ryffel, Orleans France; C57BL/6 μMT, MD4, and CD40-/- mice by Prof. D. Gray, Edin-
burgh, UK; C57BL/6 IL-4Rα–/–, IL-5–/–, and BALB/c GATA-1 Δ-dbl mice by Prof. J. Allen and
Dr S. Babayan, Edinburgh, UK. C57BL/6 FcRγ–/–x C3–/–and CCR2–/– mice were maintained in
Lausanne, Switzerland, C57BL/6 4get x Mcpt8Cre mice [26] in Erlangen, Germany, C57BL/6
IL-25–/– mice in the Malaghan Institute, New Zealand and C57BL/6 LysM-+/gfp in Washington
University in St. Louis, USA. HES, heat-denatured HES and adult somatic extract (“HEx”) was
produced from adultH. polygyrus bakeri (originally provided by Professor JM Behnke, Univer-
sity of Nottingham, UK) as described elsewhere [17,69,70]. Mice were immunized essentially
as before [17] with 5 μg HES in alum adjuvant i.p., then boosted with 1 μg in alum on days 28
and 35, before challenge with 200 H. polygyrus L3 generally 1–2 weeks later. Fecal egg counts
were determined on days 14, 21 and 28 post-challenge, and intestinal adult worms counted as
indicated. For passive immunization, total serum IgG from day 28 post-infection control or
HES immunized C57BL/6 mice was purified using a AKTA prime fast protein liquid chroma-
tography (LC) with a HiTrap protein G HP column, dialysed into PBS, and then injected into
naïve recipient C57BL/6 mice (1mg) on days -1, 0, 1, 3, 5, 7, 10, 13, 15, 17, 20, 22, 24 and 27
post-challenge withH. polygyrus. The ACK-2 hybridoma was provided by Prof. Richard Gren-
cis, and purified as above. Anti-Gr-1 clone RB6-8C5 was produced in-house at Bioceros, Neth-
erlands. Anti-Ly6G clone 1A8 was purchased from Bio-X-Cell. Antibody depletion regimes
were as follows; ACK-2 (1 mg i.p.) on days -1, 0, 1, 3 and 5 post-challenge, 1A8 (500 μg i.p.)
and RB6-8C5 (250μg i.p.) on days -1, 0, 1, 3, 5 and 7 post-challenge. Control mice received rat
IgG purified from serum as above.
Ethics statement
All animal protocols adhered to the guidelines of the UK Home Office, complied with the Ani-
mals (Scientific Procedures) Act 1986, were approved by the University of Edinburgh Ethical
Review Committee, and were performed under the authority of the UK Home Office Project
Licence number 60/4105.
Cell isolation and FACS
Mesenteric lymph node and lamina propria cells were isolated for antigen-specific restimula-
tion, surface and intracellular staining, or polyclonal stimulation for intracellular cytokine
staining, as will be described elsewhere [12]. For FACS analysis, single cell suspensions were
stained with live/dead aqua (Invitrogen) as per manufacturer’s instructions, washed into FACS
buffer (PBS with 0.5% BSA and 0.05% sodium azide), blocked with 500 μg/ml rat IgG (sigma)
for 10 min on ice, then surface stained with the following fluorochrome-conjugated antibodies:
CD45.2 (clone 104), CD11b (M170), F4/80 (BM8), Ly6C (HK1.4), Ly6G (1A8), CD3 (17A2),
CD19 (6D5), CD8α (53–6.7), Gr-1 (RB6-8C5), CD11c (N418), MHCII (M5/114.15.2), CD4
(RM4-5), anti-mouse IgM (RMM-1), anti-mouse IgG1 (RMG1-1), CD23 (B3B4), CD24 (M1/
69), CD117 (2B8); all from Biolegend. CD49b (DX5) and siglecF PE (E50-2440) from BD Phar-
mingen, and CD103 (M290) from eBioscience. Intracellular antibodies were: IL-4 (11B11), IL-
17A (TC11-18H10.1), IFNγ(XMG1.2) from Biolegend; IL-5 (TRFK5), IL-13 (ebio13A), Foxp3
(FJK-16) from eBioscience. Samples were acquired using an LSR II or Canto flow cytometer
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(BD Bioscience), and analysed with flowjo software (Tree Star). Lamina propria CD11b+Ly6G+
cells were sorted using a FACS aria (BD).
Cytokine and antibody ELISA
Serum antibody ELISA were performed as previously described [17] by coating with HES
(1 μg/ml) or purified native VAL proteins (0.1 μg/ml), and detected using HRP-conjugated
anti-mouse IgM, G1, G2a, A and E secondary antibodies (Southern Biotech). Controls included
naïve mouse serum, day 28 primary infection sera and day 14 secondary infection sera. Gut ho-
mogenates were made in 1X cell lysis buffer (Cell Signaling) supplemented with PMSF protease
inhibitor (Sigma) using a TissueLyzer (Qiagen). Serum and gut homogenate mouse mMCP-1
levels were determined with a commercially available ELISA kit (eBioscience).
Quantitative PCR
RNA was TRIzol (Invitrogen) extracted from duodenum (approx. 5 mm) according to manu-
facturer’s instructions. RNA (1–2 μg) was reverse transcribed with M-MLV reverse transcrip-
tase (Promega), and cDNA transcript levels measured by quantitative PCR on a Roche
Lightcycler 480 II with SYBR Green (Roche) using primers described previously [71].
Histology, immunohistochemistry, cytospins and two-photon microscopy
Transverse sections (5 μm) were cut from formalin-fixed paraffin-embedded duodenum and
stained with either hemotoxylin and eosin or toluidine blue according to standard techniques.
Pictures were taken using a DFC290 compound microscope and Application Suite software
(both Leica). For antibody staining, paraffin sections were incubated with CD11b-FITC,
Gr1-biotin/streptavidin APC. Intravital two-photon microscopy was carried out as previously
described [22]. Briefly, mice were anesthetized with isofluorane, the peritoneal cavity opened,
and duodenum (approximately 2–3 cm from the stomach) secured to a plastic coverslip with
vetbond (3M). Non-targeted Q-dots (Qtracker 655nm, Invitrogen) were injected retro-
orbitally to label the lumen of the blood vessels. Fluorescence was excited at 750 or 890 nm and
images (~225 x 250 μm) were acquired from the serosal surface of intact intestine at 25 frames/
second. Images were rendered and cells tracked using Imaris v7 (Bitplane, USA). Leukocyte re-
cruitment was analysed as described in Kreisel et al [72].
2-D gel electrophoresis, western blotting, immunoprecipation and
LC-MS
Identification of antibody targets in HES involved two separate approaches. First, for Fig. 6C, E
and F, HES was biotin-labeled, immunoprecipitated with polyclonal sera from immunized
mice, separated by 2-D gel electrophoresis and stained with HRP-conjugated Streptavidin as
previously described [17]. Mice were immunized with specific VAL proteins purified from un-
labeled HES by immunoprecipitation with Sepharose bead-conjugated mouse anti-VAL-1
(clone 5-S36), VAL-2 (clone 5-S2), VAL-3 mAb (clone 5-S1) and VAL-4 (clone 2–11). These
mAb were generated from the spleens of secondary infected H. polygyrusmice and were conju-
gated as before [17]. In a second approach, shown in Fig. 6G to identify antigenic proteins by
LC-MS, total serum Ig from uninfected C57BL/6 mice immunized with VAL-1, 2 and
3-depleted HES was isolated by ammonium sulfate precipitation and bead-conjugated as
above. Immunoprecipitation of unlabeled total HES was carried out as above, and bound pro-
teins were eluted and subjected to LC-MS/MS analysis as before [69]. Proteins were identified
by comparison with aH. polygyrus transcriptomic assembly comprised of five different life-
Vaccine Immunity to Intestinal Helminth Parasite
PLOS Pathogens | DOI:10.1371/journal.ppat.1004676 March 27, 2015 16 / 22
cycle stages (L3, day 3 larvae, day 5 larvae, adult and egg; Harcus et al, manuscript in prepara-
tion). MudPit scoring was used for LC-MS with a p<0.05 significance threshold, with single
peptide hits more stringently filtered for expect values<0.01. False discovery rate for peptides
at p<0.05 was 2.15%.
Statistical analysis
Statistical analyses were carried out as indicated with Prism 6 (Graphpad Software Inc.). Nor-
mally distributed two-way comparisons used unpaired t tests, and multiple comparisons used
one-way ANOVA, followed by Tukey’s test. If normality was not achieved, Mann–Whitney
(for two-way comparisons) and Kruskal–Wallis tests (for multiple comparisons, followed
by Dunn’s test) were used. P values of<0.05 were considered significant.  p<0.05,  p<0.01,
 p<0.001,  p<0.0001.
Supporting Information
S1 Fig. Characterisation of protective MLN and tissue responses post-challenge. (Related to
Fig. 2) A. Naïve and d 7 MLN CD4+ intracellular IL-4 and IL-13. Graph shows IL-4/IL-13
double positive CD4+ cells from naïve, d 7 or d 14 MLN. B. As (A) showing MLN CD4+
cells intracellular IL-4 and IFNγin MLN. C. As (A) showing proportion of MLN CD4+ cells
that are Foxp3+.D. As (A) showing proportion of MLN CD4+ Foxp3+ cells that are CD103+.
E. Intestinal CD45+CD11b+ cell types in naïve and d 7 post-challenge control and HES-
vaccinated mice; siglecF+, Ly6G+, F4/80intLy6C+, F4/80intLy6C– indicated. F. qPCR for
RELMα, RELMβ, Ym-1 and Arg-1 in duodenums from naïve (black) and d 7 post-challenge
PBS controls (white) and HES immunized (black). Expression normalized to naïve levels.
All data representative of two independent experiments. Significance determined by unpaired
t-test as indicated.
(TIFF)
S2 Fig. B cells, antibodies and immunity. (Related to Fig. 3). A. Faecal egg burdens (d 14, 21,
28) in control or vaccinated C57BL/6 and μMTmice. B, C. Adult worm (d 28) and faecal egg
burdens (d 14, 21, 28) in control or vaccinated C57BL/6 and MD4 mice.D. Adult worm bur-
dens (d 28) in control or vaccinated C57BL/6 and CD40–/– mice. E. Pre-challenge anti-HES
IgG1 titres in mice from (D). F. Anti-HES IgG1 in passive immunized mice following PBS in-
jection (white), d 28 post-infection control IgG (green) or d 28 post-infection vaccine IgG (red)
at d1 post-challenge (i.e. after 2x injections) or d28 (i.e. after 13x injections). Pre-challenge
HES vaccine sera included for comparison. Significance in (A-F) determined by unpaired t-test
as indicated. Representative of two experiments.
(TIFF)
S3 Fig. Antibody-dependent and independent mechanisms of immunity. (Related to Fig. 4).
A, B. Fecal egg counts (d 14, 21, 28) and pre-challenge anti-HES IgG1 titers in control and vac-
cinated C57BL/6 and IL-4Rα–/– mice. Day 28 primary and d 14 secondary C57BL/6 infection
sera included for comparison in (B). Pooled from two experiments. C. Immunoprecipitation of
biotin-labeled HES antigens with pre-challenge vaccine sera from C57BL/6 and IL-4Rα–/–
mice. Mwmarkers and pI as indicated.D. MLN SiglecF expression from naïve, d7 and d14
post-challenge PBS and HES mice. Representative of two experiments. E-F. MLN SiglecF+ fre-
quency in d 7 MLN from control and vaccinated C57BL/6 and IL-5–/– (E) and BALB/c and
Δdbl-GATA-1 (F) mice. G. Adult worm burdens (d 28) in control or vaccinated C57BL/6 and
IL-5–/– mice. Pooled from two experiments with 4–5 mice per group.H-I. Pre-challenge anti-
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HES IgG1 titers pre-challenge from C57BL/6 and IL-5–/– mice (H) and BALB/c and Δdbl-
GATA-1 (I) mice. Representative of two experiments. J. Toluidine blue+ MC cell numbers per
20 villus crypt units in duodenal sections from naïve and d 2, 5, 7 and 9 post-challenge PBS
(blue) or HES immunized (red) mice. K. Splenic CD45.2lo c-kit+ mast cells in naïve and in-
fected C57BL/6 mice following ACK mAb treatment as detailed in material and methods. L,
M. Serum (L) and gut tissue (M) mMCP-1 levels from (K). Significance determined by un-
paired t-test (A, B, D, G-J) or ANOVA (K-M) as indicated.
(TIFF)
S4 Fig. Type 2 immunity in IL-17RA–/–mice. (Related to Fig. 5). A. Intracellular IL-5 and IL-
17A production by live CD45+ lineage– ICOS+ lamina propria cells from naïve and d 3 post-
challenge C57BL/6 and IL-17RA–/– mice. Lineage– cells were gated as CD45.2+ lymphocytes
that were CD3–CD4–CD8α–CD19–Gr-1–CD11b–CD11c–MHCII–F4/80–CD49b–. Representa-
tive of two experiments. B. Cytospins of FACS sorted CD11b+ Ly6G+ SiglecF–F4/80– lamina
propria cells from naïve and d 7 infected C57BL/6 duodenums. Scale bar represents 10 μm.
(TIFF)
S5 Fig. Characterisation of protective antigens. (Related to Fig. 6). A. Pre-challenge anti-HES
IgG1 titers in C57BL/6 mice immunized with PBS, native HES or heat-treated (HT) HES. Sig-
nificance determined by unpaired t-test as indicated. B-F. 2-D silver stained gels of HES, VAL-
1/2/3-depleted HES or native purified VAL-1, 2 and 3. VAL-1, 2 and 3 indicated in blue, red
and green, respectively. Mw markers and pI as indicated. G-J. Pre-challenge anti native VAL-1
(G), 2 (H), 3 (I) and HES (J) IgG1 titers following immunization with PBS (black), HES
(white), VAL-1/2/3-depleted HES (blue) and VAL-1/2/3 cocktail (red). K. Faecal egg burdens
(d 14, 21, 28) in mice from (G-J). Significance determined by ANOVA Vs PBS/alum control. L.
2-D silver stained gel of native purified VAL-4 (brown circle) with Mw markers and pI as indi-
cated.M. Pre-challenge anti native VAL-4 titers following immunization with PBS (black),
HES (white) or VAL-1/2/3/4-depleted HES (blue). Data representative of two experiments (A,
G-K) or multiple batches (B-F, L).
(TIFF)
S1 Movie. LysM-GFP+ cell arrest and extravasation in infected tissue of immune mice.
Intra-vital imaging of duodenal vasculature in uninfected LysM-GFP mice (1 A) or mice in-
fected with H. polygyrus 3 days earlier (1 B, C), following immunisation with PBS-alum (1 B)
orH. polygyrus ES antigens in alum (1 C). Green Fluorescent Protein (GFP) is expressed under
the LysM promoter in neutrophils and monocytes, Q-tracker 655 (red) was injected intrave-
nously to stain vascular contents, and the images were captured at 890 nm at which wavelength
collagen fibrils emit second harmonic blue fluorescence. Two-photon imaging is real-time with
scale bar representing 50 μm. Note most blood myeloid cells transit the vasculature of uninfect-
ed mice very rapidly without interacting with the vascular endothelium (1 A) Following infec-
tion cells show significant endothelial adhesion and crawling (1 B); however, extravasation is
limited. In contrast, mice immunised against HES show extensive cell arrest and extravasation
(1 C), indicating that immunity overcomes parasite inhibition of tissue inflammation.Day 5
H. polygyrus larvae are enveloped by LysM-GFP+ cells in the duodenal submucosa. Intra-
vital imaging of day 5 post-infection H. polygyrus nematode larvae encysted in the duodenal
submucosa, in LysM-GFP mice. Images were captured at 750nm at which wavelength the nem-
atode larvae autofluoresce in the blue range; intravascular Q-tracker 655 (red) is also visible.
Two-photon imaging is real-time with scale bar representing 50 μm. Images compare control
mice receiving PBS-alum injections (D) with HES-immunized animals (E). In immune mice,
GFP+ myeloid cells show more extensive envelopment of the larvae, which are still alive at this
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point but are constrained and impaired by the cellular infiltrate. Also, note leakage of intravas-
cular Q-tracker 655 into the parasite tissue niche, suggesting the larvae is exposed to vascular
contents (including IgG1 antibodies).
(ZIP)
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